LyrArc Article Gist
The large decline in sales of copy paper in 2012 and the increasing use of devices like the iPad mean less demand for printers and costly ink cartridges, which will affect H-P's printing division.

LyrArc Article Gist
Softbank founder Masayoshi Son's life as a Korean immigrant in Japan, the early beginnings and tendency to set and achieve ambitious targets.

LyrArc Article Gist
HDFC Bank CEO, Aditya Puri, has succeeded with conservative practices in lending. It is now India's second biggest lender by market value, after the government owned State Bank of India. HDFC's lending to consumers has doubled since 2008 under Puri. He believes in prudent lending and keeps an autographed copy of Michael Lewis's The Big Short in his office. This has enabled Puri to avoid the losses experienced by other banks such ICICI, and with India's growing economy HDFC has profit increases of over 30% for the last decade. HDFC is adding 2 million customers a year, says Puri. The bad loan ratio is estimated to be 0.2% in the third quarter of 2011, one tenth of that at State Bank of India. India's largest mortgage lender, Housing Development Finance Corporation, is the largest shareholder with 23%. Puri says he will focus on growth in India, and will continue to avoid taking the kind of risks that would make depositor's lose sleep at night.

LyrArc Article Gist
Analysts say Abbott has paid a steep price for India's Piramal Health Care. Abbott is buying the Indian drug company for $3.72 billion, which is 48% above Piramal's market cap. Going by Piramal sales of $500 million a year , this is 7 times expected sales. Daiichi Sankyo paid 4 times sales for Ranbaxy in 2008. Analysts say this will give Abbott a 7% market share in India's branded generics market. Yet this market is highly fragmented with the top 20 makers having 60% of the market and many small companies.

LyrArc Article Gist
Gap Inc. plans to open 2 stores in Beijing and Shanghai in late 2010. It is part of an expansion strategy that covers markets in Hong Kong, Turkey, Saudi Arabia and Romania. The stores in China will be company owned.

LyrArc Article Gist
Nestle agreed to pay $11.85 billion for Pfizer's infant nutrition business. This business came with Pfizer's $68 billion acquisition of Wyeth Pharmaceutical. Nestle outbid Danone for the deal, paying what analysts say is a 20% premium. The deal was important for Nestle to secure its position in the fast growing infant nutrition business in China. With the acquisition Nestle would have a 9.7% market share in China, after Mead Johnson with 11.7%, and about tied with Danone at 9.8%. Nestle has a 17% share of the $27 billion market worldwide for baby milk formula, followed by Mead Johnson Nutrition with 15% and Danone with 13%, according to Euromonitor International. The deal was important for Nestle because its market share in China was small compared to its rivals- only 2.3%.

LyrArc Article Gist
Telefonica offers part of its dividend in shares to conserve cash and considers IPO listings for operations in Germany and Latin America. Earnings decline by 54% in the first quarter of 2012. Shares have lost over 30% in 2012. Net debt is 57 billion euros, larger than its market capitalization and forecast at 2.7 times Ebitda. JP Morgan estimates show that sale of call center Atento for 1 billion euros, and stakes in in China Unicom and O2 in the Czech Republic could bring an additional 6 billion euros, which would bring debt down to 2 times Ebitda.

LyrArc Article Gist
Jonathan Rockoff interviews Pfizer CEO, Ian Read. Read says Pfizer will make up for the loss of patent protection on Lipitor sales of $10.7 billion. He plans to cut Pfizer's $8.1 billion research budget to $6.5 billion. Pfizer sold one unit that makes drugs in capsule form for $2.4 billion. He looks to growth in Lyrica for fibromyalgia, and Prevnar for pneumococcal vaccine. And sees growth in China and emerging markets. Even with government ordered price reductions in China, increase in volume sales make up for the price reductions. Asked about the closing of the Pfizer labs in Sandwich, England, Read says the competitors were ahead of Pfizer in areas of research at Sandwich such as allergy, respiratory and urology. Pfizer will move scientists from Groton, Connecticut, to Cambridge, Mass, to bring scientists together in hubs of innovation such as La Jolla, Boston, and Cambridge, England. In the old days Groton served as a location because it was near a river, fermentation was needed and water access had to be provided. Read says Pfizer will focus on the core- neuroscience, cardiovascular medicine, oncology, inflammation, immunology and vaccines, specialized units for pain, sensory disorders and biosimiliars- and make sure this is producing results....